Research progress on blood lipid management in type 2 diabetic patients
CHENG Li1 SHI Xiang2
1.Department of Clinical Medicine,Jishou University School of Medicine,Hu′nan Province,Jishou 416000,China;2.Department of Geriatrics,Xiangxi Autonomous Prefecture People′s Hospital of Hu′nan Province,Jishou 416000,China
Abstract：Diabetes is an independent risk factor for cardio-cerebrovascular disease,and cardio-cerebrovascular disease is the main cause of complications and death in diabetic patients.Lipogenic treatment can significantly reduce the risk of cardiovascular events in diabetic patients and benefit patients with type 2 diabetes.By consulting the guidelines for the prevention and treatment of type 2 diabetes in China,Europe and the United States,the guidelines for the prevention and treatment of abnormal blood lipids,and some clinical experiments,the research in detail describes some questions like whether or not patients with type 2 diabetes need to start lipid-regulating treatment,when they need to start lipid-regulating treatment,and setting the target value of lipid-regulating,which type of lipid-regulating agent,the dose of the drug,and whether it is necessary to continue to use Statins after the blood lipids are up to the standard,etc.Through the study,the management of patients with type 2 diabetes is further understood.
Jacobson TA，Ito MK，Maki KC，et al.National lipid association recomendations for patient-centered management of dyslipidemia part 1-full report[J].J Clin Lipidol，2015，9（2）：129-169.
[2]
任路平，宋光耀.2型糖尿病大血管并发症防治[J].临床荟萃，2016，31（9）：949-952.
[3]
Cushman WC，Evans GW，Byington RP，et al.Effects of intensive blood-pressure control in type 2 diabetes mellitus[J].N Engl J Med，2010，362（17）：1575-1585.
[4]
Saremi A，Bahn GD，Reaven PD.A link between hypoglycemia and progression of atherosclerosis in the veterans affairs diabetes trial（VADT）[J].Diabetes Care，2016，39（3）：448-454.
Verges B.Pathophysiology of diabetic dyslipidaemia：where are we?[J].Diabetologia，2015，58（5）：886-899.
[5]
The ADVANCE Collaborative Group.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[J].N Engl J Med，2008，358（24）：2560-2572.
[7]
Rosenblit PD.Common medications used by patients with type 2 diabetes mellitus：what are their effects on the lipid profile?[J].Cardiovasc Diabetol，2016，15（1）：1-13.
[8]
Collins R，Armitage J，Parish S，et al.MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes：a randomised placebo-controlled trial[J].Lancet，2003，361（9374）：2005-2016.
[9]
Colhoun HM，Betteridge D，Durrington PN，et al.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study（CARDS）：multicentre randomised placebo-controlled trial[J].Lancet，1900，364（9435）：685-696.
[12]
Ji L，Hu D，Pan C，et al.Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients[J].Am J Med，2013，126（10）：925.e11-925.e22.
[18]
Stone NJ，Robinson JG，Lichtenstein AH，et al.American College of Cardiology/American Heart Association Task Force on Practice G 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults：a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol，2014，63（25 Pt B）：2889-2934.
[19]
Rabar S，Harker M，Flynn N，et al.On behalf of the Guideline Development Group.Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease：summary of updated NICE guidance[J].BMJ，2014，349（349）：1-6.
[21]
Catagano AL， Graham I，De Backer G，et al.2016 ESC/EAS Guidelines for the Management of dyslipidaemias：The task force for the management of dyslipidaemias of the European society of cardiology （ESC） and European atherosclerosis society（EAS）developed with the special contribution of the European association for cardiovascular prevention&ehabilitation （EACPR）[J].Atheroselerosis，2016，37（39）：281-344.
[23]
Dai W，Huang XS，Zhao SP.No evidence to support highintensity statin in Chinese patients with coronary heart disease[J].Int J Cardiol，2016，204：57-58.
[24]
HPS2-THRIVE Collaborative Group.HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant：trial design，pre-specified muscle and liver outcomes，and reasons for stopping study treatment[J].Eur Heart J，2013，34（17）：1279-1291.
[25]
Collins R，Reith C，Emberson J，et al.Interpretation of the evidence for the efficacy and safety of statin therapy[J].Lancet，2016，388（10059）：2532-2561.
Stroes ES，Thompson PD，Corsini A，et al.Statin-associated muscle symptoms：impact on statin therapy Society Consensus Panel Statement on Assessment，Aetiology and Management[J].Eur Heart J，2015，36（17）：1012-1022.
Naci H.Capsule commentary on Ott et al，do statins impair cognition？A systematic review and meta-analysis of randomized controlled trials[J].J Gen Intern Med，2015，30（3）：347.
京公网安备 11010502046607号